重新思考卵巢癌：改善预后的建议。
Rethinking ovarian cancer: recommendations for improving outcomes.
机构信息
Ovarian Cancer Action Research Centre, Imperial College London Hammersmith Campus, Du Cane Road, London W12 0NN, UK.
出版信息
Nat Rev Cancer. 2011 Sep 23;11(10):719-25. doi: 10.1038/nrc3144.
Abstract
There have been major advances in our understanding of the cellular and molecular biology of the human malignancies that are collectively referred to as ovarian cancer. At a recent Helene Harris Memorial Trust meeting, an international group of researchers considered actions that should be taken to improve the outcome for women with ovarian cancer. Nine major recommendations are outlined in this Opinion article.
摘要
在对被统称为卵巢癌的人类恶性肿瘤的细胞和分子生物学的理解方面已经取得了重大进展。在最近的海伦娜·哈里斯纪念信托会议上，一个国际研究小组考虑了为改善卵巢癌患者的治疗效果而应采取的行动。本文提出了九点主要建议。
相似文献
1
Rethinking ovarian cancer: recommendations for improving outcomes.重新思考卵巢癌：改善预后的建议。
Nat Rev Cancer. 2011 Sep 23;11(10):719-25. doi: 10.1038/nrc3144.
2
Current research and treatment for epithelial ovarian cancer. A Position Paper from the Helene Harris Memorial Trust.上皮性卵巢癌的当前研究与治疗。海伦·哈里斯纪念信托基金的立场文件。
Eur J Cancer. 2003 Sep;39(13):1818-27. doi: 10.1016/s0959-8049(03)00511-2.
3
Targeted therapies for treatment of recurrent ovarian cancer.复发性卵巢癌的靶向治疗
Clin Adv Hematol Oncol. 2014 Mar;12(3):158-62.
4
Current treatment and clinical trials in ovarian cancer.卵巢癌的当前治疗方法和临床试验。
Expert Opin Investig Drugs. 2010 Apr;19(4):521-34. doi: 10.1517/13543781003647966.
5
10th Biennial Helene Harris Memorial Trust meeting.第十届海伦·哈里斯纪念信托基金两年一度会议。
Cancer Res. 2006 Mar 15;66(6):2904-6. doi: 10.1158/0008-5472.CAN-05-2093.
6
Clinical trials referral resource. Clinical trials in ovarian cancer; Part 1.临床试验转诊资源。卵巢癌临床试验；第1部分。
Oncology (Williston Park). 2002 Nov;16(11):1498-9, 1504, 1506-7.
7
Conclusions and recommendations from the Helene Harris Memorial Trust Fifth Biennial International Forum on Ovarian Cancer, May 4-7, 1995, Glasgow, UK.1995年5月4日至7日在英国格拉斯哥举行的海伦·哈里斯纪念信托基金第五届卵巢癌两年一度国际论坛的结论与建议。
Int J Gynecol Cancer. 1995 Nov;5(6):449-458. doi: 10.1046/j.1525-1438.1995.05060449.x.
8
Ovarian cancer treatment: The end of empiricism?卵巢癌治疗：经验主义的终结？
Cancer. 2015 Sep 15;121(18):3203-11. doi: 10.1002/cncr.29481. Epub 2015 Jun 10.
9
Conclusions and recommendations from the Helene Harris Memorial Trust Fourth Biennial International Forum on Ovarian Cancer 11-14 May 1993, Toronto, Canada.1993年5月11日至14日于加拿大多伦多举行的海伦·哈里斯纪念信托基金第四届卵巢癌两年一度国际论坛的结论与建议。
Int J Gynecol Cancer. 1994 Mar;4(2):135-143. doi: 10.1046/j.1525-1438.1994.04020135.x.
10
The current status of PARP inhibitors in ovarian cancer.PARP抑制剂在卵巢癌中的现状
Tumori. 2016 Oct 13;102(5):433-440. doi: 10.5301/tj.5000558. Epub 2016 Sep 24.
引用本文的文献
1
Ex vivo 3D micro-tumour testing platform for predicting clinical response to platinum-based therapy in patients with high-grade serous ovarian cancer.用于预测高级别浆液性卵巢癌患者对铂类疗法临床反应的体外3D微肿瘤检测平台
NPJ Precis Oncol. 2025 Aug 30;9(1):306. doi: 10.1038/s41698-025-01080-8.
2
Epidemiological and clinicopathological characteristics of ovarian cancer in Syria during the war years: a national multicenter retrospective study (2017-2021).叙利亚战争期间卵巢癌的流行病学和临床病理特征：一项全国多中心回顾性研究（2017 - 2021年）
BMC Cancer. 2025 Aug 22;25(1):1359. doi: 10.1186/s12885-025-14784-8.
3
The emerging role of miR-362 in cancer: expression and function across different cancer types.miR-362在癌症中的新作用：不同癌症类型中的表达与功能
Med Oncol. 2025 Jul 26;42(9):380. doi: 10.1007/s12032-025-02900-4.
4
Precision sniper for solid tumors: CAR-NK cell therapy.实体瘤的精准狙击：CAR-NK细胞疗法。
Cancer Immunol Immunother. 2025 Jul 24;74(9):275. doi: 10.1007/s00262-025-04106-z.
5
CAMKKβ supports growth and viability of epithelial ovarian cancer in vitro and in vivo.钙调神经磷酸酶激酶β（CAMKKβ）在体外和体内均支持上皮性卵巢癌的生长和存活。
Sci Rep. 2025 Jul 17;15(1):25913. doi: 10.1038/s41598-025-11584-9.
6
Actin-Like Protein 6A as an Oncogene and Therapeutic Target in Cancer.肌动蛋白样蛋白6A作为癌症中的一种癌基因和治疗靶点
Int J Med Sci. 2025 Jun 12;22(12):2906-2918. doi: 10.7150/ijms.113736. eCollection 2025.
7
The Role of Neutrophil Extracellular Traps (NETs) in the Pathogenesis of Ovarian Cancer: New Insight and Future Perspectives.中性粒细胞胞外诱捕网（NETs）在卵巢癌发病机制中的作用：新见解与未来展望
Mol Biotechnol. 2025 Jul 12. doi: 10.1007/s12033-025-01473-x.
8
TTK activates ATR through RPA2 phosphorylation to promote olaparib resistance in ovarian cancer.TTK通过RPA2磷酸化激活ATR，以促进卵巢癌对奥拉帕利的耐药性。
Commun Biol. 2025 Jul 5;8(1):1011. doi: 10.1038/s42003-025-08444-7.
9
Phosphodiesterase 7: a potential novel therapeutic target in ovarian cancer.磷酸二酯酶7：卵巢癌潜在的新型治疗靶点
Front Pharmacol. 2025 Jun 4;16:1566330. doi: 10.3389/fphar.2025.1566330. eCollection 2025.
10
Single-cell transcriptomics identify a chemotherapy-resistance related cluster overexpressed CLIC3 in ovarian cancer.单细胞转录组学鉴定出卵巢癌中一个与化疗耐药相关的、过表达CLIC3的细胞簇。
Discov Oncol. 2025 Jun 14;16(1):1099. doi: 10.1007/s12672-025-02882-9.
本文引用的文献
1
Ovarian cancer spheroids use myosin-generated force to clear the mesothelium.卵巢癌细胞球利用肌球蛋白产生的力清除间皮。
Cancer Discov. 2011 Jul;1(2):144-57. doi: 10.1158/2159-8274.CD-11-0010.
2
Interleukin-6 as a therapeutic target in human ovarian cancer.白细胞介素 6 作为人类卵巢癌的治疗靶点。
Clin Cancer Res. 2011 Sep 15;17(18):6083-96. doi: 10.1158/1078-0432.CCR-11-0945. Epub 2011 Jul 27.
3
Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells.肿瘤缺氧通过 CCL28 和 T（调节）细胞促进耐受和血管生成。
Nature. 2011 Jul 13;475(7355):226-30. doi: 10.1038/nature10169.
4
Integrated genomic analyses of ovarian carcinoma.卵巢癌的综合基因组分析。
Nature. 2011 Jun 29;474(7353):609-15. doi: 10.1038/nature10166.
5
Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial.筛查对卵巢癌死亡率的影响：前列腺癌、肺癌、结直肠癌和卵巢癌（PLCO）癌症筛查随机对照试验。
JAMA. 2011 Jun 8;305(22):2295-303. doi: 10.1001/jama.2011.766.
6
Mucinous carcinomas of the ovary and colorectum: different organ, same dilemma.卵巢和结直肠黏液性癌：不同器官，同样困境。
Lancet Oncol. 2011 Oct;12(11):1071-80. doi: 10.1016/S1470-2045(11)70058-4. Epub 2011 May 25.
7
HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer.HDAC4 调控的 STAT1 激活介导卵巢癌铂类耐药。
Cancer Res. 2011 Jul 1;71(13):4412-22. doi: 10.1158/0008-5472.CAN-10-4111. Epub 2011 May 13.
8
Modeling high-grade serous ovarian carcinogenesis from the fallopian tube.从输卵管建模高级别浆液性卵巢癌发生。
Proc Natl Acad Sci U S A. 2011 May 3;108(18):7547-52. doi: 10.1073/pnas.1017300108. Epub 2011 Apr 18.
9
Exploring palliative treatment outcomes in women with advanced or recurrent ovarian clear cell carcinoma.探讨晚期或复发性卵巢透明细胞癌女性的姑息治疗结局。
Gynecol Oncol. 2011 Jul;122(1):107-10. doi: 10.1016/j.ygyno.2011.03.011. Epub 2011 Apr 3.
10
Genomic analysis reveals the molecular heterogeneity of ovarian clear cell carcinomas.基因组分析揭示了卵巢透明细胞癌的分子异质性。
Clin Cancer Res. 2011 Mar 15;17(6):1521-34. doi: 10.1158/1078-0432.CCR-10-1688.
Zotero 插件